These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 10197581

  • 1. Insights from Bcl-2 and Myc: malignancy involves abrogation of apoptosis as well as sustained proliferation.
    Cory S, Vaux DL, Strasser A, Harris AW, Adams JM.
    Cancer Res; 1999 Apr 01; 59(7 Suppl):1685s-1692s. PubMed ID: 10197581
    [Abstract] [Full Text] [Related]

  • 2. The functional basis of c-myc and bcl-2 complementation during multistep lymphomagenesis in vivo.
    Marin MC, Hsu B, Stephens LC, Brisbay S, McDonnell TJ.
    Exp Cell Res; 1995 Apr 01; 217(2):240-7. PubMed ID: 7698223
    [Abstract] [Full Text] [Related]

  • 3. BCL-2 gene family and the regulation of programmed cell death.
    Korsmeyer SJ.
    Cancer Res; 1999 Apr 01; 59(7 Suppl):1693s-1700s. PubMed ID: 10197582
    [Abstract] [Full Text] [Related]

  • 4. Transformation of follicular lymphoma to Burkitt-like lymphoma within a single lymph node.
    Mukhopadhyay S, Readling J, Cotter PD, Shrimpton AE, Sidhu JS.
    Hum Pathol; 2005 May 01; 36(5):571-5. PubMed ID: 15948125
    [Abstract] [Full Text] [Related]

  • 5. Role of "cancer stem cells" and cell survival in tumor development and maintenance.
    Adams JM, Kelly PN, Dakic A, Carotta S, Nutt SL, Strasser A.
    Cold Spring Harb Symp Quant Biol; 2008 May 01; 73():451-9. PubMed ID: 19022754
    [Abstract] [Full Text] [Related]

  • 6. Molecular mechanisms of transcriptional control of bcl-2 and c-myc in follicular and transformed lymphoma.
    Arcinas M, Heckman CA, Mehew JW, Boxer LM.
    Cancer Res; 2001 Jul 01; 61(13):5202-6. PubMed ID: 11431360
    [Abstract] [Full Text] [Related]

  • 7. Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1.
    Eischen CM, Packham G, Nip J, Fee BE, Hiebert SW, Zambetti GP, Cleveland JL.
    Oncogene; 2001 Oct 25; 20(48):6983-93. PubMed ID: 11704823
    [Abstract] [Full Text] [Related]

  • 8. Paradoxical inhibition of c-myc-induced carcinogenesis by Bcl-2 in transgenic mice.
    de La Coste A, Mignon A, Fabre M, Gilbert E, Porteu A, Van Dyke T, Kahn A, Perret C.
    Cancer Res; 1999 Oct 01; 59(19):5017-22. PubMed ID: 10519417
    [Abstract] [Full Text] [Related]

  • 9. Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties.
    Bearss DJ, Lee RJ, Troyer DA, Pestell RG, Windle JJ.
    Cancer Res; 2002 Apr 01; 62(7):2077-84. PubMed ID: 11929828
    [Abstract] [Full Text] [Related]

  • 10. Role of bcl-2 in Epstein-Barr virus-induced malignant conversion of Burkitt's lymphoma cell line Akata.
    Komano J, Takada K.
    J Virol; 2001 Feb 01; 75(3):1561-4. PubMed ID: 11152530
    [Abstract] [Full Text] [Related]

  • 11. Expression of apoptosis and cell cycle related genes in proliferating and colcemid arrested cells of divergent lineage.
    Gallaher BW, Berthold A, Klammt J, Knüpfer M, Kratzsch J, Bartsch M, Kiess W.
    Cell Mol Biol (Noisy-le-grand); 2000 Feb 01; 46(1):79-88. PubMed ID: 10726974
    [Abstract] [Full Text] [Related]

  • 12. A human Burkitt's lymphoma cell line carrying t(8;22) and t(14;18) translocations.
    Kiefer T, Schüler F, Knopp A, Wimmer M, Hirt C, Schaefer HE, Dölken G.
    Ann Hematol; 2007 Nov 01; 86(11):821-30. PubMed ID: 17622530
    [Abstract] [Full Text] [Related]

  • 13. Antiapoptotic BCL-2 is required for maintenance of a model leukemia.
    Letai A, Sorcinelli MD, Beard C, Korsmeyer SJ.
    Cancer Cell; 2004 Sep 01; 6(3):241-9. PubMed ID: 15380515
    [Abstract] [Full Text] [Related]

  • 14. The great MYC escape in tumorigenesis.
    Dang CV, O'donnell KA, Juopperi T.
    Cancer Cell; 2005 Sep 01; 8(3):177-8. PubMed ID: 16169462
    [Abstract] [Full Text] [Related]

  • 15. WAP-TAg transgenic mice and the study of dysregulated cell survival, proliferation, and mutation during breast carcinogenesis.
    Li M, Lewis B, Capuco AV, Laucirica R, Furth PA.
    Oncogene; 2000 Feb 21; 19(8):1010-9. PubMed ID: 10713684
    [Abstract] [Full Text] [Related]

  • 16. Id2 is dispensable for myc-induced lymphomagenesis.
    Nilsson JA, Nilsson LM, Keller U, Yokota Y, Boyd K, Cleveland JL.
    Cancer Res; 2004 Oct 15; 64(20):7296-301. PubMed ID: 15492249
    [Abstract] [Full Text] [Related]

  • 17. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
    Soda G, Antonaci A, Bosco D, Nardoni S, Melis M.
    J Exp Clin Cancer Res; 1999 Sep 15; 18(3):363-7. PubMed ID: 10606183
    [Abstract] [Full Text] [Related]

  • 18. Iron specific growth inhibition of Burkitt's lymphoma cells in vitro, associated with a decrease in translocated c-myc expression.
    Habel ME, Lemieux R, Jung D.
    J Cell Physiol; 2005 Apr 15; 203(1):277-85. PubMed ID: 15468060
    [Abstract] [Full Text] [Related]

  • 19. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways.
    Mathas S, Rickers A, Bommert K, Dörken B, Mapara MY.
    Cancer Res; 2000 Dec 15; 60(24):7170-6. PubMed ID: 11156427
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.
    Cutrona G, Carpaneto EM, Ponzanelli A, Ulivi M, Millo E, Scarfì S, Roncella S, Benatti U, Boffa LC, Ferrarini M.
    Cancer Res; 2003 Oct 01; 63(19):6144-8. PubMed ID: 14559793
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.